BR112018006925A2 - métodos de tratamento de lesões ou patologias associadas com um edema do snc - Google Patents

métodos de tratamento de lesões ou patologias associadas com um edema do snc

Info

Publication number
BR112018006925A2
BR112018006925A2 BR112018006925A BR112018006925A BR112018006925A2 BR 112018006925 A2 BR112018006925 A2 BR 112018006925A2 BR 112018006925 A BR112018006925 A BR 112018006925A BR 112018006925 A BR112018006925 A BR 112018006925A BR 112018006925 A2 BR112018006925 A2 BR 112018006925A2
Authority
BR
Brazil
Prior art keywords
edema
snc
conditions associated
reducing
lesions
Prior art date
Application number
BR112018006925A
Other languages
English (en)
Inventor
Martin Jacobson Sven
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of BR112018006925A2 publication Critical patent/BR112018006925A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente tecnologia é destinada a reduzir ou a tratar um edema neurológico e patologias associadas com os inibidores do canal sur1-trpm4. em algumas modalidades, os métodos incluem: a redução da deterioração neurológica tardia ou a prevenção do óbito, a redução do deslizamento da linha média cerebral, a redução do grau de invalidez em um sujeito, a compensação dos níveis de glicemia de um sujeito tratado com um inibidor do canal sur1-trpm4, a prevenção de um edema cerebral, o monitoramento da atividade das enzimas hepáticas associado com o tratamento de lesões ou patologias associadas com um edema do snc, ou o monitoramento da atividade cardíaca associado com o tratamento de lesões ou patologias associadas com um edema do snc.
BR112018006925A 2015-10-07 2016-10-07 métodos de tratamento de lesões ou patologias associadas com um edema do snc BR112018006925A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Publications (1)

Publication Number Publication Date
BR112018006925A2 true BR112018006925A2 (pt) 2018-10-16

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006925A BR112018006925A2 (pt) 2015-10-07 2016-10-07 métodos de tratamento de lesões ou patologias associadas com um edema do snc

Country Status (15)

Country Link
US (2) US20180280325A1 (pt)
EP (1) EP3359162B1 (pt)
JP (3) JP7349786B2 (pt)
KR (1) KR20180063296A (pt)
CN (2) CN115737816A (pt)
AU (2) AU2016335767B2 (pt)
BR (1) BR112018006925A2 (pt)
CA (1) CA3001321A1 (pt)
EA (1) EA201890893A1 (pt)
ES (1) ES2940669T3 (pt)
HK (1) HK1257542A1 (pt)
IL (1) IL258509B2 (pt)
MA (1) MA45574A (pt)
MX (1) MX2018004286A (pt)
WO (1) WO2017062765A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872012C (en) 2012-05-08 2017-06-20 Aeromics, Llc New methods
RU2691951C2 (ru) 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
US20220226353A1 (en) * 2019-05-02 2022-07-21 Biogen Chesapeake Llc Method for treating subjects suffering from central nervous system contusions
US20230348371A1 (en) * 2020-07-17 2023-11-02 Shanghai Senhui Medicine Co., Ltd. Sulfonylurea derivative and medical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
ES2807274T3 (es) 2002-03-20 2021-02-22 Univ Maryland Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
US8557867B2 (en) 2007-06-22 2013-10-15 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of NCCa-ATP channels for therapy
US8277845B2 (en) * 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
KR20220000943A (ko) * 2010-07-19 2022-01-04 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법

Also Published As

Publication number Publication date
JP7349786B2 (ja) 2023-09-25
JP2023053274A (ja) 2023-04-12
AU2016335767B2 (en) 2022-10-06
US11951085B2 (en) 2024-04-09
CN115737816A (zh) 2023-03-07
MA45574A (fr) 2019-05-15
IL258509A (en) 2018-05-31
US20220125750A1 (en) 2022-04-28
EA201890893A1 (ru) 2018-09-28
AU2016335767A8 (en) 2018-06-28
KR20180063296A (ko) 2018-06-11
HK1257542A1 (zh) 2019-10-25
EP3359162A1 (en) 2018-08-15
MX2018004286A (es) 2018-08-09
JP2021073317A (ja) 2021-05-13
CN108348534A (zh) 2018-07-31
AU2016335767A1 (en) 2018-05-24
IL258509B (en) 2022-12-01
WO2017062765A1 (en) 2017-04-13
IL258509B2 (en) 2023-04-01
EP3359162A4 (en) 2019-08-28
CA3001321A1 (en) 2017-04-13
JP2018530564A (ja) 2018-10-18
US20180280325A1 (en) 2018-10-04
ES2940669T3 (es) 2023-05-10
EP3359162B1 (en) 2022-12-21
AU2022279369A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
BR112018006925A2 (pt) métodos de tratamento de lesões ou patologias associadas com um edema do snc
PH12018502355A1 (en) Enzyme inhibitors
WO2020086726A3 (en) Nerve stimulation for treating migraine and other headache conditions
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
WO2015117032A8 (en) Treatment systems and methods for affecting glands and other targeted structures
EP3447491A3 (en) Diagnosis and treatments relating to th2 inhibition
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
BR112017024212A2 (pt) sequências de uricases melhoradas e métodos de tratamento
PH12018501313A1 (en) Augmented acid alpha-glucosidase for the treatment of pompe disease
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
GB201202561D0 (en) Treatment of skin disorders
WO2021203103A3 (en) Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
MX2021008943A (es) Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
BR112021018591A2 (pt) Compostos e usos dos mesmos
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
MX2021002006A (es) Tratamiento del cancer de mama triple negativo con inhibicion dirigida del factor de crecimiento transformante beta (tgf-b).
EP4132967A4 (en) METHODS OF PREVENTING SARS-COV-2 INFECTION AND TREATMENT OF COVID-19
ZA202104786B (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
MY197563A (en) Kimchi for preventing or treating helicobacter pylori-associated diseases
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]